Retinitis pigmentosa: genes and disease mechanisms

Stefano Ferrari, Enzo Di Iorio, Vanessa Barbaro, Diego Ponzin, Francesco S Sorrentino, Francesco Parmeggiani, Stefano Ferrari, Enzo Di Iorio, Vanessa Barbaro, Diego Ponzin, Francesco S Sorrentino, Francesco Parmeggiani

Abstract

Retinitis pigmentosa (RP) is a group of inherited disorders affecting 1 in 3000-7000 people and characterized by abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium of the retina which lead to progressive visual loss. RP can be inherited in an autosomal dominant, autosomal recessive or X-linked manner. While usually limited to the eye, RP may also occur as part of a syndrome as in the Usher syndrome and Bardet-Biedl syndrome. Over 40 genes have been associated with RP so far, with the majority of them expressed in either the photoreceptors or the retinal pigment epithelium. The tremendous heterogeneity of the disease makes the genetics of RP complicated, thus rendering genotype-phenotype correlations not fully applicable yet. In addition to the multiplicity of mutations, in fact, different mutations in the same gene may cause different diseases. We will here review which genes are involved in the genesis of RP and how mutations can lead to retinal degeneration. In the future, a more thorough analysis of genetic and clinical data together with a better understanding of the genotype-phenotype correlation might allow to reveal important information with respect to the likelihood of disease development and choices of therapy.

Keywords: Syndromic retinitis pigmentosa; X-linked; dominant; mutations.; non-syndromic retinitis pigmentosa; recessive; retina.

Figures

Fig. (1).
Fig. (1).
Pattern of autosomal dominant RP inheritance.
Fig. (2).
Fig. (2).
Pattern of autosomal recessive RP inheritance.
Fig. (3).
Fig. (3).
Pattern of X-linked RP inheritance.
Fig. (4).
Fig. (4).
Haematoxylin-stained section of the human retina (scale bar = 100µm).

References

    1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795–1809.
    1. Marigo V. Programmed cell death in retinal degeneration: targeting apoptosis in photoreceptors as potential therapy for retinal degeneration. Cell Cycle. 2007;6(6):652–655.
    1. Hamel C. Retinitis pigmentosa. Orphanet J. Rare Dis. 2006;1:40.
    1. Grover S, Fishman GA, Anderson RJ, Tozatti MS, Heckenlively JR, Weleber RG, Edwards AO, Brown J., Jr Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology. 1999;106(9):1780–1785.
    1. Bhattacharya SS, Wright AF, Clayton JF, Price WH, Phillips CI, McKeown CM, Jay M, Bird AC, Pearson PL, Southern EM. Close genetic linkage between X-linked retinitis pigmentosa and a restriction fragment length polymorphism identified by recombinant DNA probe L1.28. Nature. 1984;309(5965):253–255.
    1. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog. Retin. Eye Res. 2010;29(5):335–375.
    1. Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. Arch. Ophthalmol. 2007;125:151–158.
    1. Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, Chen N, Goletz P, Ma JX, Crouch RK, Pfeifer K. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat. Genet. 1998;20(4):344–351.
    1. Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma JX. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc. Natl. Acad. Sci. U S A. 2005;102(35):12413–12418.
    1. Murray AR, Fliesler SJ, Al-Ubaidi MR. Rhodopsin: the functional significance of Asn-linked glycosylation and other post-translational modifications. Ophthalmic Genet. 2009;30(3):109–120.
    1. Rosenfeld PJ, Cowley GS, McGee TL, Sandberg MA, Berson EL, Dryja TP. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat. Genet. 1992;1(3):209–213.
    1. Gorbatyuk MS, Knox T, LaVail MM, Gorbatyuk OS, Noorwez SM, Hauswirth WW, Lin JH, Muzyczka N, Lewin AS. Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc. Natl. Acad. Sci. U S A. 2010;107(13):5961–5966.
    1. Chadderton N, Millington-Ward S, Palfi A, O'Reilly M, Tuohy G, Humphries MM, Li T, Humphries P, Kenna PF, Farrar GJ. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol. Ther. 2009;17(4):593–599.
    1. Audo I, Bujakowska K, Mohand-Saïd S, Lancelot ME, Moskova-Doumanova V, Waseem NH, Antonio A, Sahel JA, Bhattacharya SS, Zeitz C. Prevalence and novelty of PRPF31 mutations in French autosomal dominant rod-cone dystrophy patients and a review of published reports. BMC Med. Genet. 2010;11:145.
    1. Waseem NH, Vaclavik V, Webster A, Jenkins SA, Bird AC, Bhattacharya SS. Mutations in the gene coding for the pre-mRNA splicing factor, PRPF31, in patients with autosomal dominant retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 2007;48(3):1330–1334.
    1. Vithana EN, Abu-Safieh L, Pelosini L, Winchester E, Hornan D, Bird AC, Hunt DM, Bustin SA, Bhattacharya SS. Expression of PRPF31 mRNA in patients with autosomal dominant retinitis pigmentosa: a molecular clue for incomplete penetrance? Invest. Ophthalmol. Vis. Sci. 2003;44(10):4204–4209.
    1. Loewen CJ, Moritz OL, Molday RS. Molecular characterization of peripherin-2 and rom-1 mutants responsible for digenic retinitis pigmentosa. J. Biol. Chem. 2001;276(25):22388–22396.
    1. Dryja TP, Hahn LB, Kajiwara K, Berson EL. Dominant and digenic mutations in the peripherin/RDS and ROM1 genes in retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 1997;38(10):1972–1982.
    1. Ali RR, Sarra GM, Stephens C, Alwis MD, Bainbridge JW, Munro PM, Fauser S, Reichel MB, Kinnon C, Hunt DM, Bhattacharya SS, Thrasher AJ. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet. 2000;25(3):306–310.
    1. Liu Q, Lyubarsky A, Skalet JH, Pugh EN Jr, Pierce EA. RP1 is required for the correct stacking of outer segment discs. Invest. Ophthalmol. Vis. Sci. 2003;44(10):4171–4183.
    1. Liu Q, Zuo J, Pierce EA. The retinitis pigmentosa 1 protein is a photoreceptor microtubule-associated protein. J. Neurosci. 2004;24(29):6427–6436.
    1. Cai X, Conley SM, Naash MI. RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet. 2009;30(2):57–62.
    1. Samardzija M, von Lintig J, Tanimoto N, Oberhauser V, Thiersch M, Remé CE, Seeliger M, Grimm C, Wenzel A. R91W mutation in Rpe65 leads to milder early-onset retinal dystrophy due to the generation of low levels of 11-cis-retinal. Hum. Mol. Genet. 2008;17(2):281–292.
    1. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008;358(21):2231–2239.
    1. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U S A. 2008;105(39):15112–15117.
    1. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 2008;358(21):2240–2248.
    1. Tsang SH, Burns ME, Calvert PD, Gouras P, Baylor DA, Goff SP, Arshavsky VY. Role for the target enzyme in deactivation of photoreceptor G protein in vivo. Science. 1998;282(5286):117–121.
    1. Tsang SH, Tsui I, Chou CL, Zernant J, Haamer E, Iranmanesh R, Tosi J, Allikmets R. A novel mutation and phenotypes in phosphodiesterase 6 deficiency. Am. J. Ophthalmol. 2008;146(5):780–788.
    1. Dvir L, Srour G, Abu-Ras R, Miller B, Shalev SA, Ben-Yosef T. Autosomal-recessive early-onset retinitis pigmentosa caused by a mutation in PDE6G, the gene encoding the gamma subunit of rod cGMP phosphodiesterase. Am. J. Hum. Genet. 2010;87(2):258–264.
    1. Barragan I, Abd El-Aziz MM, Borrego S, El-Ashry MF, O’Driscoll C, Bhattacharya SS, Antinolo G. Linkage validation of RP25 using the 10K GeneChip array and further refinement of the locus by new linked families. Ann. Hum. Genet. 2008;72(Pt 4):454–462.
    1. Veltel S, Wittinghofer A. RPGR and RP2: targets for the treatment of X-linked retinitis pigmentosa? Expert. Opin. Ther. Targets. 2009;13(10):1239–1251.
    1. Vervoort R, Lennon A, Bird AC, Tulloch B, Axton R, Miano MG, Meindl A, Meitinger T, Ciccodicola A, Wright AF. Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nat. Genet. 2000;25(4):462–466.
    1. Millan JM, Aller E, Jaijo T, Blaco-Kelly F, Gimenez-Pardo A, Ayuso C. An update on the genetics of Usher Syndrome. J. Ophthalmol. 2011 DOI: 10.1155/2011/417217.
    1. Héon E, Westall C, Carmi R, Elbedour K, Panton C, Mackeen L, Stone EM, Sheffield VC. Ocular phenotypes of three genetic variants of Bardet-Biedl syndrome. Am. J. Med. Genet. A. 2005;132A(3):283–287.
    1. Azari AA, Aleman TS, Cideciyan AV, Schwartz SB, Windsor EA, Sumaroka A, Cheung AY, Steinberg JD, Roman AJ, Stone EM, Sheffield VC, Jacobson SG. Retinal disease expression in Bardet-Biedl syndrome-1 (BBS1) is a spectrum from maculopathy to retina-wide degeneration. Invest. Ophthalmol. Vis. Sci. 2006;47(11):5004–5010.
    1. Moore SJ, Green JS, Fan Y, Bhogal AK, Dicks E, Fernandez BA, Stefanelli M, Murphy C, Cramer BC, Dean JC, Beales PL, Katsanis N, Bassett AS, Davidson WS, Parfrey PS. Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort study. Am. J. Med. Genet. A. 2005;132(4):352–360.
    1. Teebi AS. Autosomal recessive disorders among Arabs: an overview from Kuwait. J. Med. Genet. 1994;31:224–233.
    1. Daiger SP, Sullivan LS, Bowne SJ, Birch DG, Heckenlively JR, Pierce EA, Weinstock GM. Targeted high-throughput DNA sequencing for gene discovery in retinitis pigmentosa. Adv. Exp. Med. Biol. 2010;664:325–331.
    1. Bowne SJ, Sullivan LS, Koboldt DC, Ding L, Fulton R, Abbott RM, Sodergren EJ, Birch DG, Wheaton DH, Heckenlively JR, Liu Q, Pierce EA, Weinstock GM, Daiger SP. Identification of Disease-Causing Mutations in Autosomal Dominant Retinitis Pigmentosa (adRP) Using Next-Generation DNA Sequencing. Invest. Ophthalmol. Vis. Sci. 2011;52(1):494–503.
    1. Musarella MA, Macdonald IM. Current concepts in the treatment of retinitis pigmentosa. J. Ophthalmol. 2011;2011:753547.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever